Untitled

doi:10.13040/ijpsr.0975-8232.8(4).1664-70

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCOS usually leads to metabolic disturbances, infertility, and various long-term health 4,15 complications. The management of PCOS involves a m u l t i d i s c i p l i n a r y a p p ro a c h , i n c l u d i n g p h a r m a c o l o g i c a l i n t e r v e n t i o n s , l i fe s t y l e modifications, and sometimes assisted reproductive 4,15 technologies. Among pharmacological options, two commonly used treatments are Myo-Inositol [16][17][18][19] and Metformin.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome

Latif,

Rajar,

Yousuf

et al. 2024

L&S

View full text Add to dashboard Cite

Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic ovary syndrome.Study Design: Cross-sectional study.Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the normalization of menstrual cycles and the achievement of ovulation.Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively. The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively. Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with p-value=0.001.Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of polycystic ovary syndrome.How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z. Comparison of Efficacy Between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. Life and Science. 2024; 5(1): 48-53. doi: http://doi.org/10.37185/LnS.1.1.486

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome

Latif,

Rajar,

Yousuf

et al. 2024

L&S

View full text Add to dashboard Cite

show abstract

Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background Multiple oral insulin-sensitizing agents, such as metformin, thiazolidinediones, inositols, and berberine, have been proven safe and efficacious in improving the endocrine, metabolic, and reproductive abnormalities seen in polycystic ovary syndrome (PCOS), providing more options for healthcare providers and patients. These oral insulin sensitizers are more convenient, practical, and economic than agents that need to be injected. A comparison of the clinical effectiveness of the four different classes of oral insulin sensitizers in PCOS has not been explored, leading to clinical uncertainty about the optimal treatment pathway. The present study aims to compare the effects of oral insulin sensitizers on endocrine and metabolic profiles in women with PCOS. Methods We identified randomized controlled trials for PCOS from a variety of databases, published from January 2005 to October 2020. Outcomes included changes in menstrual frequency, improvements in hyperandrogenism and glucolipid metabolism and adverse side effects. A random-effects network meta-analysis was performed. Results Twenty-two trials comprising 1079 patients with PCOS were included in this study. Compared with metformin, treatment with myo-inositol + d-chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31–93.58]). Myo-inositol + d-chiro-inositol and metformin + thiazolidinediones combination therapies were superior to respective monotherapies in reducing total testosterone levels. Thiazolidinediones, metformin + thiazolidinediones, and myo-inositol + d-chiro-inositol were associated with a lower insulin resistance index (HOMA-IR) compared with that in metformin alone (mean differences: − 0.72 [95% CI (− 1.11)–(− 0.34)] to − 0.89 [95% CI (− 1.460)–(− 0.32)]). Metformin + thiazolidinediones treatment was associated with lower triglyceride levels compared with that in metformin and thiazolidinediones monotherapy, while thiazolidinediones was superior to metformin in increasing high-density lipoprotein cholesterol and decreasing fasting plasma glucose, triglycerides, low-density lipoprotein cholesterol, and gastrointestinal adverse events. Conclusions Ours is the first study to report that for women with PCOS, myo-inositol combined with d-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone. Myo-inositol combined with d-chiro-inositol is particularly efficacious in menstrual recovery. Thiazolidinediones and metformin combined with thiazolidinediones improve lipid metabolism better than metformin alone. Trial registration PROSPERO CRD42020211524

show abstract

Association of insulin resistance and PCOS and its effect on women’s reproductive function

Burlakova¹,

Merkulova²,

Loginova³

et al. 2022

Probl. reprod.

View full text Add to dashboard Cite

Untitled

Cited by 4 publications

References 15 publications

Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome

Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome

Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis

Association of insulin resistance and PCOS and its effect on women’s reproductive function

Contact Info

Product

Resources

About